Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/130342TETRAVALENT FZD AND WNT CO-RECEPTOR BINDING ANTIBODY MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/IB2021/061972 Applicant ANTLERA THERAPEUTICS INC. Inventor ANGERS, Stephane
Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway and methods for their use.
2.WO/2022/133042CEA5 BINDING MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/063727 Applicant BIOARDIS, LLC Inventor HAERIZADEH, Farzad
Disclosed herein are carcinoembryonic antigen 5 (CEA5)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.
3.WO/2022/133057TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY
WO 23.06.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2021/063746 Applicant ARTIVA BIOTHERAPEUTICS, INC. Inventor HWANG, Yu Kyeong
Provided herein are, among other things, methods for treating a patient suffering from a CD20+ cancer
4.WO/2022/133492COMPOSITIONS AND METHODS FOR GENERATING ANTI-TUMOR IMMUNE RESPONSE
WO 23.06.2022
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No PCT/US2021/073007 Applicant BEYONDSPRING PHARMACEUTICALS, INC. Inventor HUANG, Lan
Disclosed herein are compositions comprising dehydrophenylahistin analogs such as plinabulin and an anti-CD47 agent for treating cancer. Also disclosed here are methods of treating cancer by co-administering the dehydrophenylahistin analog and one or more anti-CD47 agent to a subject in need thereof. Some embodiments, the one or more anti-CD47 agent is an anti-CD47 antibody molecule capable of binding CD47, as well as fragments of these monospecific antibodies that are immunologically active and still bind to CD47.
5.WO/2022/130281ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
WO 23.06.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/IB2021/061863 Applicant JANSSEN BIOTECH, INC. Inventor HARRISON, Diane D.
The present invention relates to compositions and methods utilizing anti-TNF antibodies or antigen binding fragments thereof in a treatment of active Ankylosing Spondylitis (AS), e.g., a treatment utilizing the anti-TNF antibody having heavy chain complementarity-determining region (CDR) amino acid sequences SEQ ID NOS:40-42 and light chain CDR amino acid sequences SEQ ID NOS:43-45.
6.WO/2022/130341TETRAVALENT FZD AND WNT CO-RECEPTOR BINDING ANTIBODY MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/IB2021/061971 Applicant ANTLERA THERAPEUTICS INC. Inventor ANGERS, Stephane
Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway and methods for their use.
7.WO/2022/132636HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIES
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/063086 Applicant AMMAX BIO, INC. Inventor HSU, Chung-Chiang
Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v% of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.
8.WO/2022/126687ANTI-CLAUDIN18.2 ANTIGEN-BINDING FRAGMENT OR ANTIBODY, AND USE THEREOF
WO 23.06.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2020/138240 Applicant GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD Inventor LUO, Min
Provided are an anti-Claudin18.2 antigen-binding fragment or antibody, and the use thereof. CDR3 of a heavy chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO:3. CDR3 of a light chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO:6. The provided antigen-binding fragment and anti-Claudin18.2 antibody can specifically bind to a variety of sources of Claudin18.2 proteins, have no binding effect on other proteins, and have a high specificity. In addition, a chimeric antigen receptor and a CAR-T cell prepared by means of the antibody have obvious cytotoxicity on cells stably expressing the Claudin 18.2 protein.
9.WO/2022/127842BISPECIFIC ANTIBODY TARGETING IL-17A AND IL-36R AND APPLICATION THEREOF
WO 23.06.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/138634 Applicant SHANGHAI HUAOTA BIOPHARMACEUTICAL CO., LTD. Inventor XU, Jingen
Provided are a bispecific antibody targeting IL-17A and IL-36R and an application thereof. Particularly, provided is a bispecific antibody targeting IL-17A and IL-36R and having high affinity and high biological activity. the antibody can implement high-affinity binding to IL-36R and IL-17A, and can block the binding of IL-36R ligands (α, β, γ) to IL-36R and the binding of IL-17A to IL-17R, thereby treating and/or preventing IL-36 and/or IL-17 related diseases.
10.WO/2022/130182REVERSAL BINDING AGENTS FOR ANTI-NATRIURETIC PEPTIDE RECEPTOR 1 (NPR1) ANTIBODIES AND USES THEREOF
WO 23.06.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/IB2021/061664 Applicant NOVARTIS AG Inventor ADACHI, Yuichiro
The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).